In this study, we examined changes in muscle mass and strength among elderly type 2 diabetes patients using Semaglutide, aiming to provide evidence-based guidance for its clinical application
Side effects of such drugs may include gastrointestinal issues like nausea and abdominal pain
Other diabetes medication classes offer alternatives if GLP-1 therapy proves unsuitable: SGLT2 inhibitors (such as dapagliflozin or empagliflozin) provide cardiovascular and renal benefits without affecting gastric emptying, though require adequate renal function and carry risks of genital infections and diabetic ketoacidosis DPP-4 inhibitors (such as sitagliptin) work on the incretin system but with less pronounced gastrointestinal effects note these should not be combined with GLP-1 receptor agonists Traditional agents including metformin, sulfonylureas, or insulin may be appropriate depending on individual circumstances Any medication change should be made in consultation with your diabetes specialist or GP, considering your overall glycaemic control, cardiovascular risk profile, and treatment goals, in line with NICE NG28 guidance
Notably, no participants reported drinking more after starting the medication
The beyond-use date indicates the last day the medication should be used to ensure its safety and effectiveness
